Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Coherus Biosciences (CHRS) just unveiled an announcement.
Coherus BioSciences, Inc. has expanded its Board of Directors and appointed Rita A. Karachun, a seasoned financial expert with extensive experience at Merck & Co., Inc., and AT&T Corp., as its newest member. Ms. Karachun, also joining the Audit Committee, will serve as a Class II director until the 2025 annual meeting. With her notable track record, including leading finance and accounting for AT&T’s IPO, she brings valuable expertise to the board. Additionally, she has been granted a stock option and will receive standard compensation and indemnification as per the company’s policies for non-employee directors.
See more data about CHRS stock on TipRanks’ Stock Analysis page.